Ntanasis-Stathopoulos, I. (Ioannis)

Filtering

2019 - 201912020 - 20231

Settings

Author search.filters.isAuthorOfPublication.81f85249-34c0-4f57-99d7-80c26718f555

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy
    (Ovid Technologies (Wolters Kluwer Health), 2019) Kanellias, N. (Nikolaos); Gavriatopoulou, M. (Maria); Kostopoulos, I.V. (Ioannis V.); Ntanasis-Stathopoulos, I. (Ioannis); Tsitsilonis, O.E. (Ourania E.); Migkou, M. (Magdalini); Fotiou, D. (Despina); Spyropoulou-Vlachou, M. (Marilyn); Argyriou, A.T. (Alexandra T.); Paiva, B. (Bruno); Rousakis, P. (Pantelis); Dimopoulos, M.A. (Meletios A.); Ziogas, D.C. (Dimitrios C.); Kastritis, E. (Efstathios); Terpos, E. (Evangelos); Eleutherakis-Papaiakovou, E. (Evangelos); Trougakos, I.P. (Ioannis P.); Papanota, A.M. (Aristea-Maria)
    Minimal residual disease (MRD) was monitored in 52 patients with sustained CR (≥2 years) after frontline therapy using next-generation flow (NGF) cytometry. 25% of patients initially MRD- reversed to MRD+. 56% of patients in sustained CR were MRD+; 45% at the level of 10−5; 17% at 10−6. All patients who relapsed during follow-up were MRD+ at the latest MRD assessment, including those with ultra-low tumor burden. MRD persistence was associated with specific phenotypic profiles: higher erythroblasts’ and tumor-associated monocytes/macrophages’ predominance in the bone marrow niche. NGF emerges as a suitable method for periodic, reproducible, highly-sensitive MRD-detection at the level of 10−6.
  • Thumbnail Image
    Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
    (2023) Moreau, P. (Philippe); Boccadoro, M. (Mario); Delforge, M. (M.); Engelhardt, M. (Monika); Schjesvold, F.H. (Fredrik H.); Ntanasis-Stathopoulos, I. (Ioannis); Zweegman, S. (Sonja); Ludwig, H. (Heinz); Hajek, R. (R.); Sonneveld, P. (Pieter); Einsele, H. (Hermann); Donk, N.W.C.J. (Niels W.C.J.) van de; Dimopoulos, M.A. (Meletios A.); Gay, F. (Francesca); Terpos, E. (Evangelos); Driessen, C. (Cristoph); Vangsted, A.J. (Annette Juul); San-Miguel, J.F. (Jesús F.); Cook, G. (Gordon)
    In the post-pandemic COVID-19 period, human activities have returned to normal and COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an increased risk for breakthrough infections and severe COVID-19 outcomes, including hospitalization and death. The European Myeloma Network has provided an expert consensus to guide patient management in this era. Vaccination with variant-specific booster vaccines, such as the bivalent vaccine for the ancestral Wuhan strain and the Omicron BA.4/5 strains, is essential as novel strains emerge and become dominant in the community. Boosters should be administered every 6-12 months after the last vaccine shot or documented COVID-19 infection (hybrid immunity). Booster shots seem to overcome the negative effect of anti-CD38 monoclonal antibodies on humoral responses; however, anti-BCMA treatment remains an adverse predictive factor for humoral immune response. Evaluation of the immune response after vaccination may identify a particularly vulnerable subset of patients who may need additional boosters, prophylactic therapies and prevention measures. Pre-exposure prophylaxis with tixagevimab/cilgavimab is not effective against the new dominant variants and thus is no longer recommended. Oral antivirals (nirmatrelvir/ritonavir and molnupiravir) and remdesivir are effective against Omicron subvariants BA.2.12.1, BA.4, BA.5, BQ.1.1 and/or XBB.1.5 and should be administered in MM patients at the time of a positive COVID-19 test or within 5 days post symptoms onset. Convalescent plasma seems to have low value in the post-pandemic era. Prevention measures during SARS-CoV-2 outbreaks, including mask wearing and avoiding crowded places, seem prudent to continue for MM patients.